These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 20734172)

  • 41. Anticholinergic drugs versus non-drug active therapies for overactive bladder syndrome in adults.
    Alhasso AA; McKinlay J; Patrick K; Stewart L
    Cochrane Database Syst Rev; 2006 Oct; (4):CD003193. PubMed ID: 17054163
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatments for overactive bladder: focus on pharmacotherapy.
    Geoffrion R;
    J Obstet Gynaecol Can; 2012 Nov; 34(11):1092-1101. PubMed ID: 23231848
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Overactive bladder (OAB): A symptom in search of a disease - Its relationship to specific lower urinary tract symptoms and conditions.
    Van Batavia JP; Combs AJ; Fast AM; Glassberg KI
    J Pediatr Urol; 2017 Jun; 13(3):277.e1-277.e4. PubMed ID: 28527720
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluation and Treatment of Overactive Bladder in Women.
    Raju R; Linder BJ
    Mayo Clin Proc; 2020 Feb; 95(2):370-377. PubMed ID: 32029089
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The past, present and future of augmentation cystoplasty.
    Biers SM; Venn SN; Greenwell TJ
    BJU Int; 2012 May; 109(9):1280-93. PubMed ID: 22117733
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [The overactive bladder syndrome].
    Verjans T; Dewandre M; Keppenne V; Leruth J; Waltregny D
    Rev Med Liege; 2023 May; 78(5-6):376-380. PubMed ID: 37350218
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The impact of overactive bladder on mental health, work productivity and health-related quality of life in the UK and Sweden: results from EpiLUTS.
    Coyne KS; Sexton CC; Kopp ZS; Ebel-Bitoun C; Milsom I; Chapple C
    BJU Int; 2011 Nov; 108(9):1459-71. PubMed ID: 21371240
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Update on the second line management of idiopathic overactive bladder].
    Chartier-Kastler E; Castro-Diaz D; De Ridder D; Everaert K; Sievert KD; Spinelli M; van Kerrebroeck P
    Prog Urol; 2009 Sep; 19(8):530-7. PubMed ID: 19699450
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Botulinum toxin for overactive bladder].
    Ziegelmüller BK; Sommer A; Bauer RM
    Urologe A; 2020 Aug; 59(8):963-972. PubMed ID: 32691107
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Overactive bladder after sling surgery.
    Sajadi KP; Vasavada SP
    Curr Urol Rep; 2010 Nov; 11(6):366-71. PubMed ID: 20803179
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Behavioral therapies for overactive bladder: making sense of the evidence.
    Milne JL
    J Wound Ostomy Continence Nurs; 2008; 35(1):93-101; quiz 102-3. PubMed ID: 18199944
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The role of prostanoids in the urinary bladder function and a potential use of prostanoid-targeting pharmacological agents in bladder overactivity treatment.
    Dobrek Ł; Thor PJ
    Acta Pol Pharm; 2015; 72(1):13-9. PubMed ID: 25850196
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment success for overactive bladder with urinary urge incontinence refractory to oral antimuscarinics: a review of published evidence.
    Campbell JD; Gries KS; Watanabe JH; Ravelo A; Dmochowski RR; Sullivan SD
    BMC Urol; 2009 Nov; 9():18. PubMed ID: 19930578
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Diagnosis and treatment of the overactive bladder.
    Wein AJ
    Urology; 2003 Nov; 62(5 Suppl 2):20-7. PubMed ID: 14662403
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Overactive bladder symptoms after midurethral sling surgery in women: Risk factors and management.
    Marcelissen T; Van Kerrebroeck P
    Neurourol Urodyn; 2018 Jan; 37(1):83-88. PubMed ID: 28631830
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The medical management of refractory overactive bladder.
    Robinson D; Giarenis I; Cardozo L
    Maturitas; 2013 Apr; 74(4):386-90. PubMed ID: 23395402
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Augmentation cystoplasty: Urodynamic and metabolic outcomes at 10-year follow-up.
    Cheng KC; Kan CF; Chu PS; Man CW; Wong BT; Ho LY; Au WH
    Int J Urol; 2015 Dec; 22(12):1149-54. PubMed ID: 26391472
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The management of overactive bladder: percutaneous tibial nerve stimulation, sacral nerve stimulation, or botulinum toxin?
    Tubaro A; Puccini F; De Nunzio C
    Curr Opin Urol; 2015 Jul; 25(4):305-10. PubMed ID: 26049873
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The satisfaction of patients with refractory idiopathic overactive bladder with onabotulinumtoxinA and augmentation cystoplasty.
    El-Azab AS; Moeen AM
    Arab J Urol; 2013 Dec; 11(4):344-9. PubMed ID: 26558103
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacotherapy of overactive bladder: epidemiology and pathophysiology of overactive bladder.
    Latini JM; Giannantoni A
    Expert Opin Pharmacother; 2011 May; 12(7):1017-27. PubMed ID: 21473706
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.